Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Stocks surged Monday, led by tech sector gains, as the market recovered from a steep decline at the end of last week that was sparked by renewed concerns about tariffs and the health of the economy.

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...

Novo Nordisk A/S (NYSE: NVO) is one of the top cheap pharmaceutical stocks to buy now. On August 1, Bernstein analyst Florent ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...